Geron (GERN) Common Equity (2010 - 2026)
Geron (GERN) posted Common Equity of $229.1 million for Q1 2026, up 1.43% sequentially from $225.9 million in Q4 2025, and down 14.59% YoY from $268.2 million in Q1 2025.
Geron (GERN) Common Equity (2010 - 2026) Analysis & Trends
Geron has reported Common Equity for 17 years, with the latest figure at $229.1 million in Q1 2026.
- Quarterly Common Equity fell 14.59% year-over-year to $229.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.1 million (down 14.59% YoY) and the FY2025 annual result came in at $225.9 million, down 19.42% from the prior year.
- Common Equity rose to $229.1 million in Q1 2026 per GERN's latest filing, from $225.9 million in the prior quarter.
- Over five years, Common Equity peaked at $344.9 million in Q1 2024 and troughed at $80.0 million in Q4 2022.
- A 5-year average of $238.0 million and a median of $259.5 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity plunged 51.54% in 2022, then soared 234.46% in 2023.
- Over 5 years, Common Equity stood at $80.0 million in 2022, then soared by 209.94% to $247.9 million in 2023, then rose by 13.06% to $280.3 million in 2024, then fell by 19.42% to $225.9 million in 2025, then increased by 1.43% to $229.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $229.1 million, $225.9 million, and $248.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 9.79 Bn |
| 10 | Geron | 1.05 Mn | -299.80 Mn | - | 218.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.61 Mn |
| Mar 31, 2026 | 229.11 Mn |
| Dec 31, 2025 | 225.87 Mn |
| Sep 30, 2025 | 248.71 Mn |
| Jun 30, 2025 | 259.53 Mn |
| Mar 31, 2025 | 268.24 Mn |
| Dec 31, 2024 | 280.32 Mn |
| Sep 30, 2024 | 292.28 Mn |
| Jun 30, 2024 | 306.70 Mn |
| Mar 31, 2024 | 344.87 Mn |
| Dec 31, 2023 | 247.95 Mn |
| Sep 30, 2023 | 290.61 Mn |
| Jun 30, 2023 | 298.43 Mn |
| Mar 31, 2023 | 326.06 Mn |
| Dec 31, 2022 | 80.00 Mn |
| Sep 30, 2022 | 108.17 Mn |
| Jun 30, 2022 | 142.05 Mn |
| Mar 31, 2022 | 97.49 Mn |
| Dec 31, 2021 | 126.42 Mn |
| Sep 30, 2021 | 151.55 Mn |